Annual report pursuant to Section 13 and 15(d)

Stock-Based Compensation - Liberty - Outstanding Awards (Details)

v3.22.0.1
Stock-Based Compensation - Liberty - Outstanding Awards (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Additional disclosures      
Total unrecognized compensation cost related to unvested equity awards $ 49    
Weighted average period of recognition related to unvested equity awards (in years) 1 year 7 months 6 days    
Options, exercises in period, total intrinsic value $ 144 $ 8 $ 163
Restricted Stock and Restricted Stock Units      
Additional disclosures      
Equity instruments other than options, vested in period, fair value $ 13 $ 45 $ 17
Liberty SiriusXM Group      
Additional disclosures      
Common stock reserved for issuance 7,400    
Liberty SiriusXM Group | Common Class A      
Number of options      
Outstanding at end of period 0    
Liberty SiriusXM Group | Common Class B      
Number of options      
Outstanding at end of period 0    
Liberty SiriusXM Group | Series C      
Number of options      
Outstanding at beginning of period 10,870    
Granted 323    
Exercised (3,823)    
Forfeited/Cancelled (1)    
Outstanding at end of period 7,369 10,870  
Exercisable at end of period 5,213    
WAEP      
Outstanding at beginning of period $ 34.96    
Granted 45.79    
Exercised 28.48    
Forfeited/Cancelled 42.62    
Outstanding at end of period 38.79 $ 34.96  
Exercisable at end of period $ 36.39    
Additional disclosures      
Weighted average remaining life, outstanding 3 years 4 months 24 days    
Weighted average remaining life, exercisable 2 years 7 months 6 days    
Aggregate intrinsic value, outstanding $ 89    
Aggregate intrinsic value, exercisable $ 75    
Liberty SiriusXM Group | Restricted Stock and Restricted Stock Units      
Additional disclosures      
Equity instruments other than options, nonvested, number 73    
Restricted stock weighted average grant-date fair value $ 41.81    
Formula One Group      
Additional disclosures      
Common stock reserved for issuance 9,100    
Formula One Group | Common Class A      
Number of options      
Outstanding at end of period 1    
WAEP      
Exercised $ 12.63    
Additional disclosures      
Weighted average period of recognition related to unvested equity awards (in years) 1 year    
Formula One Group | Common Class B      
Number of options      
Outstanding at end of period 0    
Formula One Group | Series C      
Number of options      
Outstanding at beginning of period 10,391    
Granted 773    
Exercised (2,050)    
Outstanding at end of period 9,114 10,391  
Exercisable at end of period 7,507    
WAEP      
Outstanding at beginning of period $ 31.78    
Granted 46.40    
Exercised 25.71    
Outstanding at end of period 34.38 $ 31.78  
Exercisable at end of period $ 32.42    
Additional disclosures      
Weighted average remaining life, outstanding 4 years 2 months 12 days    
Weighted average remaining life, exercisable 4 years    
Aggregate intrinsic value, outstanding $ 263    
Aggregate intrinsic value, exercisable $ 231    
Formula One Group | Restricted Stock and Restricted Stock Units      
Additional disclosures      
Equity instruments other than options, nonvested, number 138    
Restricted stock weighted average grant-date fair value $ 46.42    
Braves Group      
Additional disclosures      
Common stock reserved for issuance 3,100    
Braves Group | Common Class A      
Number of options      
Outstanding at end of period 1    
WAEP      
Exercised $ 12.35    
Additional disclosures      
Weighted average period of recognition related to unvested equity awards (in years) 1 year    
Braves Group | Common Class B      
Number of options      
Outstanding at end of period 0    
Braves Group | Series C      
Number of options      
Outstanding at beginning of period 3,475    
Granted 23    
Exercised (373)    
Outstanding at end of period 3,125 3,475  
Exercisable at end of period 649    
WAEP      
Outstanding at beginning of period $ 24.81    
Granted 30.17    
Exercised 16.39    
Outstanding at end of period 25.86 $ 24.81  
Exercisable at end of period $ 20.58    
Additional disclosures      
Weighted average remaining life, outstanding 5 years 1 month 6 days    
Weighted average remaining life, exercisable 2 years 7 months 6 days    
Aggregate intrinsic value, outstanding $ 7    
Aggregate intrinsic value, exercisable $ 5    
Braves Group | Restricted Stock and Restricted Stock Units      
Additional disclosures      
Equity instruments other than options, nonvested, number 219    
Restricted stock weighted average grant-date fair value $ 28.62